Iovance Biotherapeutics, Inc. IOVA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$79.05M+32.0% | -$71.9M+8.5% | -$91.25M-9.2% | -$111.66M-15.0% | -$116.16M-2.8% | ||
| $2.82M+9.8% | $3.72M+13.7% | $2.99M-0.5% | $3.4M+13.3% | $2.57M-13.7% | ||
| $11.27M-50.8% | $11.82M-61.9% | $11.9M-61.6% | $14.94M-51.0% | $22.92M+33.4% | ||
| -$665K+63.8% | $0— | -$2.41M-58.1% | $1.99M+236% | -$1.84M-30.5% | ||
| -$28K+36.4% | —— | —— | —— | -$44K— | ||
| -$690K-143% | $15.69M+15.6% | $6.82M-71.8% | -$11M-135% | $1.6M+1,825% | ||
| $4.93M-64.4% | $4M-78.9% | $3.18M-67.7% | —— | $13.83M+105% | ||
| $15.89M+674% | -$5.21M+14.1% | -$4.39M— | $893K+109% | $2.05M+135% | ||
| -$21.04M-1,035% | $21.17M+418% | $5.5M-56.7% | $0-100% | $2.25M+110% | ||
| $1.47M-54.9% | $661K-87.6% | —— | $6.89M— | $3.25M+155% | ||
| $5.72M+4.0% | $6.2M-42.1% | $5.8M+5.5% | $5.7M+3.6% | $5.5M+18.6% | ||
| $85K-22.7% | $14K— | —— | $30K+125% | $110K+59.4% | ||
| $1.88M-34.6% | $2.72M-14.2% | $2.92M+13.2% | $2.88M+20.2% | $2.87M+25.0% | ||
| -$2.03M+34.9% | -$2.9M+20.6% | -$2.41M+18.2% | -$2.48M+7.9% | -$3.11M-11.6% | ||
| -$72.07M+30.5% | -$52.57M+28.3% | -$78.7M-33.5% | -$67.45M+31.5% | -$103.69M+15.2% | ||
| $6.61M+6.4% | $9.32M+124% | $10.84M+374% | $7.46M+1,588% | $6.21M+48.9% | ||
| $56M-42.8% | $59.91M-32.0% | $92.14M-41.1% | $68.7M-7.6% | $97.92M-30.9% | ||
| $74M-38.3% | $70M-39.7% | $120M+9.1% | $90M-21.7% | $120M+37.9% | ||
| $11.39M-28.2% | $775K— | $17.01M+135% | $13.84M— | $15.87M+114% | ||
| $98.51M-33.9% | $55.78M— | $88.52M+86.3% | $13.07M-91.4% | $148.94M-24.7% | ||
| $4.18M-26.0% | $445K-49.4% | $466K-92.6% | $504K-49.6% | $5.64M+20.1% | ||
| $94.34M-34.2% | $56.17M+2,333% | $88.06M+110% | $13.23M-91.3% | $143.32M-26.0% | ||
| -$213K-142% | $577K+149% | —— | $739K+691% | $508K+203% | ||
| $33.44M-40.3% | $4.96M+110% | $25.69M+140% | —— | $56M+238% | ||
| $1.12M-47.8% | $1.34M-51.6% | $1.71M-35.6% | $2M-19.8% | $2.15M-8.1% | ||
| $5.72M+4.0% | $6.2M-42.1% | $5.8M+5.5% | $5.7M+3.6% | $5.5M+18.6% | ||
| -$434K-636% | $373K— | -$232K-349% | $156K— | -$59K-161% | ||
| -$28K+36.4% | —— | —— | —— | -$44K— | ||
| —— | —— | —— | —— | —— | ||
| -$2.03M+34.9% | -$2.9M+20.6% | -$2.41M+18.2% | -$2.48M+7.9% | -$3.11M-11.6% | ||
| $1.47M-54.9% | $661K-87.6% | —— | $6.89M— | $3.25M+155% | ||
| -$506K-8,333% | $3.7M— | $1.39M— | $8.32M— | -$6K— | ||
| $1.88M-34.6% | $2.72M-14.2% | $2.92M+13.2% | $2.88M+20.2% | $2.87M+25.0% | ||
| $74M-38.3% | $70M-39.7% | $120M+9.1% | $90M-21.7% | $120M+37.9% | ||
| -$5.89M+9.3% | —— | —— | -$6.79M-309% | -$6.49M-850% | ||
| —— | —— | —— | —— | $1K— | ||
| -$2.03M+34.9% | -$2.9M+20.6% | -$2.41M+18.2% | -$2.48M+7.9% | -$3.11M-11.6% | ||
| $359K+125% | —— | $1.74M+755% | $1.93M— | -$1.43M-113% | ||
| $85K-22.7% | $14K— | —— | $30K+125% | $110K+59.4% | ||
| -$78.68M+28.4% | -$61.89M+20.1% | -$89.55M-46.2% | -$74.91M+24.2% | -$109.91M+13.1% | ||
| -$78.68M+28.4% | -$61.89M+20.1% | -$89.55M-46.2% | -$74.91M+24.2% | -$109.91M+13.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.